title: Clinical trial of Tripterygium Wilfordii Hook F. in human kidney transplantation in China.
abstract: OBJECTIVE
  In this study, the effects of Triptergium Wilfordii Hook F.(T II) were assessed on human kidney allograft rejection and long-term survival.
  
  
  METHODS
  This study compared treatment with T II(T II group, n=121) to that without T II(control group, n=102) among adult first cadaveric renal transplant recipients. The T II cohort of 121 recipients were divided into a regular dosage group (n=82) and a double dosage group (n=39). No antibody induction was administered to any patient.
  
  
  RESULTS
  Biopsy-proven early acute allograft rejection occurred in 4.1% of patients in the T II group versus 24.5% of patients in the control group. No rejection or repeated rejections occurred in the double dosage group at 3 months after transplantation. Acute rejection episodes were milder in the T II than the control group. The incidence of CD25+ cells>10/ mm3 in the allografts at 3 months after transplantation was lower in the T II group than the control group, 15% and 50%, respectively. All patients tolerated T II well over the 5 years of this study. The 5-year graft survival censored for death with function was 96.7% in the T II group and 80.4% in the control group.
  
  
  CONCLUSIONS
  T II was effective to prevent renal allograft rejection and increase long-term renal allograft survival among adult cadaveric renal transplant recipients.
authors.affiliation: Research Institute of Nephrology, Jinling Hospital, and Nanjing University School of Medicine, People's Republic of China. jishuming@vip.163.com
authors.forename: S-M
authors.initials: SM
authors.lastname: Ji
authors.forename: Q-W
authors.initials: QW
authors.lastname: Wang
authors.forename: J-S
authors.initials: JS
authors.lastname: Chen
authors.forename: G-Z
authors.initials: GZ
authors.lastname: Sha
authors.forename: Z-H
authors.initials: ZH
authors.lastname: Liu
authors.forename: L-S
authors.initials: LS
authors.lastname: Li
mesh_terms: D000328:Adult; D001706:Biopsy; D002681:China; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D006085:Graft Survival / Q000187:drug effects; D029001:Herbal Medicine; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D008297:Male; D008517:Phytotherapy; D010936:Plant Extracts / Q000009:adverse effects / Q000627:therapeutic use*; D016019:Survival Analysis; D013997:Time Factors; D014184:Transplantation, Homologous; D029757:Tripterygium
chemical_list: D007166:Immunosuppressive Agents; D010936:Plant Extracts; D003404:Creatinine